Journal
NATURE NEUROSCIENCE
Volume 14, Issue 1, Pages 85-U117Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nn.2692
Keywords
-
Categories
Funding
- Parkinson's Disease Foundation
- American Parkinson Disease Association Research
- Michael J. Fox Foundation
- Hartmann Foundation
- US National Institutes of Health [NS069777, MH082522, NS064757, NS05595, NS059934, NS042762, NS047085]
- NATIONAL INSTITUTE OF MENTAL HEALTH [F30MH082522] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K02NS055995, P50NS047085, R21NS065391, R01NS042762, F30NS064757, R01NS059934, R01NS069777] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Parkinson's disease is a common neurodegenerative disorder characterized by a profound motor disability that is traceable to the emergence of synchronous, rhythmic spiking in neurons of the external segment of the globus pallidus (GPe). The origins of this pathophysiology are poorly defined for the generation of pacemaking. After the induction of a parkinsonian state in mice, there was a progressive decline in autonomous GPe pacemaking, which normally serves to desynchronize activity. The loss was attributable to the downregulation of an ion channel that is essential in pacemaking, the hyperpolarization and cyclic nucleotide-gated (HCN) channel. Viral delivery of HCN2 subunits restored pacemaking and reduced burst spiking in GPe neurons. However, the motor disability induced by dopamine (DA) depletion was not reversed, suggesting that the loss of pacemaking was a consequence, rather than a cause, of key network pathophysiology, a conclusion that is consistent with the ability of L-type channel antagonists to attenuate silencing after DA depletion.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available